Cargando…
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
PURPOSE: To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations. METHODS:...
Autores principales: | Abernethy, Amy P., Arunachalam, Ashwini, Burke, Thomas, McKay, Caroline, Cao, Xiting, Sorg, Rachael, Carbone, David P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482433/ https://www.ncbi.nlm.nih.gov/pubmed/28644837 http://dx.doi.org/10.1371/journal.pone.0178420 |
Ejemplares similares
-
Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023) -
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016) -
Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
por: Sag, Sebnem Ozemri, et al.
Publicado: (2016) -
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015) -
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)